AADACL2-AS1

Across TCGA pan-cancer cohorts, AADACL2-AS1 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated AADACL2-AS1 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher AADACL2-AS1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated AADACL2-AS1 expression acts as an unfavorable survival marker.

SARC are the cancer types where AADACL2-AS1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	DFS	Median	All	0.121	0.611	.041	6	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

AADACL2-AS1–SARC (DFS)

Open the SARC breakdown →